NSTE-ACS: Risk Stratification, Antithrombotic Therapy, and Invasive Strategy
A bedside framework for unstable angina and NSTEMI — high-sensitivity troponin pathways, GRACE/HEART triage, dual antiplatelet selection, and timing of coronary angiography.
Executive Summary
S1. Definition, Pathophysiology, and Etiology
NSTE-ACS is a clinical syndrome defined by ischemic chest discomfort or anginal-equivalent symptoms (dyspnea, jaw/arm pain, diaphoresis, syncope) without persistent ST-segment elevation on the 12-lead ECG. It is subdivided by cardiac biomarker status: NSTEMI when high-sensitivity cardiac troponin (hs-cTn) rises above the 99th-percentile upper reference limit (URL) with a dynamic change pattern, and unstable angina (UA) when ischemic symptoms occur without troponin rise. With the widespread adoption of hs-cTn assays since 2010, the UA category has shrunk dramatically — many cases formerly labeled UA now reclassify as small NSTEMIs once subclinical necrosis is detectable in the picogram range.
Underlying pathophysiology
Type 1 MI — the dominant NSTE-ACS mechanism — arises from acute atherothrombosis: rupture or erosion of a vulnerable lipid-rich plaque in an epicardial coronary artery exposes thrombogenic subendothelial collagen and tissue factor, triggering platelet adhesion (via GP Ib-vWF), activation (via thromboxane A2 and ADP), and aggregation (via GP IIb/IIIa cross-linking). Unlike STEMI, the resulting thrombus in NSTE-ACS is typically non-occlusive or subtotally occlusive, or there is brisk distal collateral flow, so transmural infarction is averted. Plaque erosion (more common in younger women) versus rupture (more common in men with high lipid burden) carries different antithrombotic implications — emerging evidence suggests erosion may be managed with antithrombotic therapy alone in selected cases (EROSION trial).
Type 2 MI — supply-demand mismatch from a non-thrombotic trigger (severe hypertension, tachyarrhythmia, hypoxemia, anemia, hypotension, severe aortic stenosis) superimposed on stable coronary disease — accounts for 25-40% of troponin-elevation hospitalizations and demands a fundamentally different management strategy: treat the precipitant, not the plaque. Distinguishing Type 1 from Type 2 is therefore the single most consequential bedside cognitive task in the NSTE-ACS workup.
| Etiology | Mechanism | Frequency | Management Pivot |
|---|---|---|---|
| Type 1 MI (plaque rupture) | Acute atherothrombosis | 50-60% | DAPT + anticoag + invasive |
| Type 1 MI (plaque erosion) | Endothelial denudation, mural thrombus | 10-15% | DAPT + anticoag (selective invasive) |
| Type 2 MI (supply-demand) | Tachy/hypoxia/HTN/anemia + fixed CAD | 25-40% | Treat precipitant; cath only if recurrent |
| Coronary spasm (vasospastic angina) | Endothelial dysfunction, smooth muscle hyperreactivity | 2-5% | CCB + nitrate; avoid beta-blocker monotherapy |
| Spontaneous coronary artery dissection (SCAD) | Intramural hematoma, false lumen | 1-4% (up to 25% in young women) | Conservative; PCI only if ongoing ischemia |
| Microvascular angina (MINOCA subtype) | Coronary microvascular dysfunction | 5-10% | Anti-anginal therapy; functional testing |
S2. Diagnosis: ECG, Troponin Algorithms, and Differential
Initial ECG (within 10 minutes of presentation)
The 12-lead ECG must be obtained and interpreted within 10 minutes of first medical contact. Diagnostic features supporting NSTE-ACS include new horizontal or downsloping ST-depression ≥0.5 mm in two contiguous leads, transient ST-elevation (<20 minutes), or new T-wave inversions ≥1 mm. Critically, a normal ECG does not exclude NSTE-ACS — up to 30% of confirmed NSTEMIs have a non-diagnostic initial ECG, mandating serial tracings (every 15-30 minutes) during the diagnostic window. ST-elevation in lead aVR with diffuse ST-depression suggests left main or three-vessel disease — a true cardiology emergency warranting immediate cath.
High-sensitivity troponin protocols
Modern hs-cTn assays detect troponin in the picogram-per-liter range, allowing accelerated 0/1h or 0/2h algorithms (vs the legacy 0/3h or 0/6h pathway). The 0/1h ESC algorithm uses three assay-specific cutoffs: a rule-out threshold (very low absolute value at 0h plus minimal Δ at 1h), an observe zone (mid-range values requiring further serial testing or imaging), and a rule-in threshold (very high baseline or significant 1h Δ). Practical caveat: hs-cTn rises in many non-ACS conditions — chronic kidney disease, sepsis, heart failure, pulmonary embolism, myocarditis — so the dynamic Δ pattern (rise and fall over serial measurements) is more specific for acute MI than any single absolute value. A flat elevated troponin in a CKD patient typically represents chronic baseline myocardial injury, not acute infarction.
HEART and GRACE risk scores
Two scoring systems dominate ED triage: the HEART score (History, ECG, Age, Risk factors, Troponin; range 0-10) and the GRACE 2.0 calculator (8 variables yielding 6-month mortality estimate). HEART 0-3 identifies a low-risk cohort with <2% 6-week MACE rate, suitable for early discharge with outpatient follow-up. HEART 4-6 is intermediate (12-17% MACE) — admit for observation and stress testing or invasive evaluation. HEART ≥7 is high-risk (50-65% MACE), mandating early invasive strategy. GRACE >140 (or troponin elevation, dynamic ST changes, hemodynamic instability, ongoing pain, recent PCI/CABG, or LVEF <40%) defines the cohort that benefits from invasive cath within 24 hours.
| Risk Tier | Criteria (any 1+) | Cath Timing | Disposition |
|---|---|---|---|
| Very high risk | Hemodynamic instability, cardiogenic shock, refractory pain, life-threatening arrhythmia, mechanical complication, acute HF | <2 hours (immediate) | CCU; emergent cath |
| High risk | Confirmed NSTEMI by hs-cTn rise/fall, dynamic ST/T changes, GRACE >140 | <24 hours (early invasive) | CCU/telemetry |
| Intermediate risk | Diabetes, eGFR <60, LVEF <40%, prior PCI/CABG, GRACE 109-140 | <72 hours | Telemetry |
| Low risk | None of the above; HEART 0-3 | Selective (stress test first) | Observation or discharge |
S3. Antithrombotic Therapy: DAPT, Anticoagulation, GP IIb/IIIa
Aspirin loading (universal)
All NSTE-ACS patients without contraindication receive aspirin 162-325 mg PO chewed immediately at first medical contact, followed by 81-100 mg PO daily indefinitely. Chewable or non-enteric-coated formulation is preferred for rapid platelet COX-1 inhibition.
P2Y12 inhibitor (universal — agent choice depends on strategy)
The P2Y12 inhibitor selection is one of the highest-impact decisions:
- Ticagrelor 180 mg PO load → 90 mg BID — preferred for most NSTE-ACS regardless of strategy (PLATO trial: 16% reduction in cardiovascular death vs clopidogrel). Reversible binding (offset 3-5 days). Side effects: dyspnea (~14%), bradyarrhythmias, hyperuricemia.
- Prasugrel 60 mg PO load → 10 mg daily (5 mg if ≥75y or <60 kg) — preferred when invasive strategy is planned and coronary anatomy is known (TRITON-TIMI 38: 19% MACE reduction vs clopidogrel). Contraindicated in prior stroke/TIA; avoid in patients ≥75y unless DM or prior MI; avoid in patients <60 kg without dose reduction.
- Clopidogrel 300-600 mg PO load → 75 mg daily — reserve for: contraindications to ticagrelor/prasugrel, concurrent oral anticoagulation (triple therapy), or high bleeding risk. Variable response due to CYP2C19 polymorphisms (loss-of-function alleles in ~30% of East Asians yield reduced platelet inhibition).
Pre-treatment timing controversy
The 2020 ESC guidelines do not recommend routine P2Y12 pre-treatment in NSTE-ACS patients planned for early invasive strategy when coronary anatomy is unknown — based on the ISAR-REACT 5 and ACCOAST trials showing no benefit and increased bleeding from upstream loading. P2Y12 inhibitor is given after coronary angiography defines the lesion and the strategy (PCI vs CABG vs medical). However, in delayed cath (>24h), STEMI, or hemodynamic instability requiring immediate stenting, upstream loading remains standard.
Parenteral anticoagulation (during hospitalization)
| Agent | Dose | Strengths | Caveats |
|---|---|---|---|
| Fondaparinux | 2.5 mg SC daily | Lowest bleeding risk; preferred for medical management | Add UFH if PCI (catheter thrombosis risk); avoid if eGFR <20 |
| Enoxaparin | 1 mg/kg SC q12h (0.75 mg/kg if ≥75y) | Predictable dosing; no monitoring | Reduce to q24h if eGFR 15-30; avoid <15 |
| Unfractionated heparin (UFH) | 60 U/kg IV bolus (max 4000) → 12 U/kg/hr (max 1000/hr) titrate to aPTT 1.5-2.5× | Reversible (protamine); preferred in renal failure or planned CABG | HIT risk; aPTT monitoring required |
| Bivalirudin | 0.75 mg/kg IV bolus → 1.75 mg/kg/hr during PCI | Lower bleeding than UFH + GP IIb/IIIa | More acute stent thrombosis vs UFH (MATRIX trial); reserve for high-bleed-risk PCI |
GP IIb/IIIa inhibitors (selective use)
Glycoprotein IIb/IIIa inhibitors (eptifibatide, tirofiban, abciximab — abciximab now discontinued in many markets) are not routinely used upstream in the modern DAPT era. They remain in the toolkit for bailout during PCI for large thrombus burden, no-reflow, or peri-procedural ischemic complication. Eptifibatide 180 mcg/kg IV bolus × 2 (10 min apart) → 2 mcg/kg/min infusion for 18-24h post-PCI. Tirofiban 25 mcg/kg IV bolus → 0.15 mcg/kg/min for 18-24h. Both require renal dose adjustment.
Bleeding risk assessment
Before committing to potent DAPT, calculate the CRUSADE score (in-hospital major bleeding) or PRECISE-DAPT score (out-of-hospital bleeding 0-12 months). High bleeding risk (PRECISE-DAPT ≥25, ARC-HBR criteria) shifts the calculus toward shorter DAPT (3-6 months) followed by P2Y12 monotherapy or aspirin alone, particularly in patients on concurrent oral anticoagulation for AF or mechanical valves. The TWILIGHT, MASTER-DAPT, and STOPDAPT-2 trials support shortened DAPT followed by ticagrelor or clopidogrel monotherapy in high-bleed-risk PCI cohorts.
S4. Invasive Strategy: Timing and Revascularization
Cath laboratory timing matrix
Invasive strategy timing is one of the most studied questions in modern NSTE-ACS care. The TIMACS, VERDICT, and EARLY trials inform the current four-tier framework:
| Timing | Indication | Evidence |
|---|---|---|
| Immediate (<2 h) | Hemodynamic instability, cardiogenic shock, refractory ischemic pain, life-threatening arrhythmia (VT/VF), mechanical complication (papillary muscle rupture, VSD), acute decompensated HF | Class I — extrapolated from STEMI |
| Early (<24 h) | Confirmed NSTEMI (hs-cTn rise/fall), dynamic ST changes, GRACE >140 | TIMACS subgroup: 28% MACE reduction in high-risk; VERDICT confirmed |
| Delayed invasive (<72 h) | Diabetes, CKD eGFR 30-60, LVEF <40%, post-MI angina, prior PCI/CABG, GRACE 109-140 | Class IIa |
| Selective invasive (after stress test) | Low risk: HEART 0-3, no troponin rise, normal ECG, stable | Outpatient stress imaging; cath only if ischemia provoked |
Revascularization choice: PCI vs CABG
Coronary anatomy from diagnostic angiography drives revascularization:
- Single-vessel disease (non-LM): PCI to culprit lesion with drug-eluting stent (DES). DAPT minimum 12 months for DES + ACS.
- Multivessel disease: SYNTAX score and Heart Team discussion. Low SYNTAX (≤22) — PCI acceptable. Intermediate (23-32) — individualize. High (>32) or left main with multivessel — CABG preferred.
- Left main disease: CABG remains gold standard; PCI acceptable for low SYNTAX (EXCEL, NOBLE trials — controversial in long-term mortality).
- Diabetes + multivessel: CABG preferred (FREEDOM trial — significant survival advantage of CABG over PCI at 5 years).
Adjunctive medical therapy
Beta-blockers metoprolol 25-50 mg PO BID within 24 hours unless contraindicated (acute HF, hypotension, bradycardia, AV block, active asthma, cocaine use). High-intensity statin atorvastatin 40-80 mg PO daily or rosuvastatin 20-40 mg PO daily regardless of baseline LDL. ACE inhibitor lisinopril 5-40 mg PO daily or ARB if intolerant; especially in LVEF <40%, anterior MI, hypertension, diabetes, or CKD. Aldosterone antagonist eplerenone 25-50 mg PO daily if LVEF ≤40% with HF symptoms or diabetes (EPHESUS trial).
S5. Special Populations and Discharge Planning
When to involve interventional cardiology immediately
(1) Hemodynamic instability or cardiogenic shock; (2) refractory ischemic chest pain despite maximal medical therapy; (3) life-threatening ventricular arrhythmia; (4) new mechanical complication (acute MR, VSD, free wall rupture); (5) recurrent dynamic ST changes; (6) failed thrombolysis (rare in NSTE-ACS but applicable when STEMI was initially suspected); (7) cardiac arrest with successful ROSC and ECG features suggesting ongoing ischemia.
Elderly (≥75 years)
Older patients derive equal or greater absolute benefit from invasive strategy (After Eighty trial: invasive vs conservative reduced MACE by 47% in NSTEMI ≥80y) but carry higher bleeding and procedural risk. Adjustments: prasugrel reduced to 5 mg daily; consider clopidogrel if prasugrel/ticagrelor not tolerated; reduce enoxaparin to 0.75 mg/kg q12h; reduce contrast volume; pre-procedure hydration for AKI prevention. Frailty assessment (Clinical Frailty Scale ≥6) may shift toward conservative strategy in selected cases.
Chronic kidney disease
CKD patients are systematically undertreated despite paradoxically higher absolute mortality benefit from guideline-directed therapy. Key adjustments: enoxaparin contraindicated if eGFR <15 (use UFH); fondaparinux contraindicated <20; reduce IV contrast (use isosmolar agent, hydration with isotonic saline 1 mL/kg/h × 6h pre-procedure and post-procedure if dialysis-dependent skip hydration). Dialysis patients require careful timing of cath relative to dialysis sessions.
Concurrent oral anticoagulation (AF, mechanical valve, VTE)
Triple therapy (OAC + aspirin + P2Y12) carries 2-3× bleeding risk vs DAPT alone. Modern strategy (AUGUSTUS, PIONEER-AF, RE-DUAL PCI, ENTRUST-AF PCI trials): drop aspirin at hospital discharge or within 1 week, continue DOAC + clopidogrel for 6-12 months, then DOAC monotherapy. Apixaban, rivaroxaban (2.5 mg BID for AF + ACS post-PCI), edoxaban, and dabigatran all studied. Avoid ticagrelor or prasugrel in triple therapy.
| Discharge Component | Specifics | Duration |
|---|---|---|
| Aspirin | 81 mg PO daily | Indefinite |
| P2Y12 inhibitor | Ticagrelor 90 mg BID (or prasugrel 10 mg daily, or clopidogrel 75 mg daily) | 12 months minimum (DES + ACS); shorter if HBR |
| High-intensity statin | Atorvastatin 80 mg or rosuvastatin 40 mg daily | Indefinite; LDL goal <55 mg/dL (ESC) or <70 (ACC/AHA) |
| Beta-blocker | Metoprolol succinate 50-200 mg daily, carvedilol 25 mg BID | Indefinite if LVEF <40%; otherwise ≥3 years |
| ACEi/ARB | Lisinopril, ramipril, losartan | Indefinite if LVEF <40%, HTN, DM, CKD |
| Aldosterone antagonist | Eplerenone 25-50 mg daily | If LVEF ≤40% + HF or DM |
| Cardiac rehabilitation | 12-week supervised exercise + education | Class I — 25% mortality reduction |
| Smoking cessation | Counseling + varenicline or NRT | Greater MACE reduction than any drug |
| Influenza vaccination | Annually | Class I (reduces MACE) |
Practice Insights: Bedside Notes on NSTE-ACS
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Troponin confirms the infarct in NSTE-ACS but says nothing about when that patient should reach the catheterization laboratory, and the consistent system change that has moved the outcomes is using the GRACE risk score in the ED note to define the invasive-strategy window, and switching morphine for fentanyl in any P2Y12-loaded patient.
hs-cTn 0/1h or 0/2h Algorithm — Rule-In and Rule-Out at the Bedside
The ESC 0/1-hour and 0/2-hour high-sensitivity troponin algorithms let experienced clinicians commit to either rule-in or rule-out within 1–2 hours of arrival in roughly 75% of patients, instead of the old 4–6-hour serial protocol. In published series, these patients with chest pain plus normal ECG plus initial hs-cTn below assay-specific rule-out threshold get the 1-hour repeat; if delta troponin is below the rule-out cutoff, rule-out is committed and outpatient evaluation booked. Patients with rising delta above rule-in threshold get committed to NSTE-ACS at hour 1 and cath plans started. The 25% who fall into the observe zone get the 3-hour repeat with cardiology consultation.
GRACE Score in the ED Note Drives Invasive Timing
The GRACE risk score (age, HR, SBP, creatinine, Killip class, ST deviation, cardiac arrest, troponin) predicts in-hospital and 6-month mortality and is the primary tool for invasive strategy timing. Routinely, experienced practice documents GRACE in the ED admission note: GRACE >140 or any very-high-risk criterion (hemodynamic instability, refractory ischemia, sustained VT, mechanical complication, recurrent dynamic ischemic ECG changes) triggers an early invasive call — <2 hours for very high risk, <24 hours for high risk. GRACE 109–140 with comorbidities (diabetes, CKD, EF <40%, prior CABG or recent PCI) gets invasive within 72 hours. GRACE <108 with no high-risk features can get a selective invasive strategy after non-invasive testing.
Skip P2Y12 Pre-Treatment in the ED
The 2020 ESC guidelines stopped recommending routine P2Y12 pre-treatment before angiography in NSTE-ACS based on the DUBIUS and ISAR-REACT 5 trials, which showed no ischemic benefit and increased bleeding risk when ticagrelor or prasugrel are given before knowing coronary anatomy. In practice seasoned clinicians load aspirin 162–325 mg at first medical contact but hold the P2Y12 inhibitor until cath confirms PCI is the plan; if CABG turns out to be the strategy, experienced clinicians have not committed the patient to a 5-day prasugrel/ticagrelor hold. ACC/AHA still allows pre-treatment, but the European evidence has changed experienced practice. The exception is true STEMI activation where pre-PCI loading remains standard.
Fentanyl, Not Morphine, in Any P2Y12-Loaded Patient
Morphine delays absorption and onset of oral P2Y12 inhibitors meaningfully — published data show ticagrelor and prasugrel peak effect is delayed by hours when morphine is co-administered, with measurable platelet reactivity persisting at the time of cath. In practice IV fentanyl 25–50 mcg titrated is the analgesic of choice in NSTE-ACS once P2Y12 has been or will be loaded; morphine is reserved for refractory pain after fentanyl, with the trade-off acknowledged. Nitroglycerin sublingual or IV remains first-line for ischemic pain control before any opioid.
Illustrative Scenario: GRACE 145 With Cath Within 18 Hours
A man in his late 60s with diabetes and prior PCI 18 months earlier presented with 4 hours of substernal chest pain. ECG showed 1 mm ST depression in V4–V6 without ST elevation; hs-cTn at 0 hours was 35 ng/L (above rule-out) and at 1 hour was 142 ng/L (clear delta above rule-in threshold). GRACE score calculated to 145 (age 68, HR 92, SBP 138, Cr 1.3, Killip I, ST depression, no arrest, elevated troponin). NSTE-ACS confirmed and high-risk category. The treating clinicians gave aspirin 325 mg, atorvastatin 80 mg, IV fentanyl 50 mcg for ongoing pain, unfractionated heparin 60 U/kg bolus + 12 U/kg/hr infusion; held the P2Y12 inhibitor pending cath. Cath at hour 18 from arrival showed a 95% in-stent restenosis in the LAD; PCI with drug-eluting stent was performed and ticagrelor 180 mg loading dose was given on the table immediately after stent deployment. He was discharged on day 4 on aspirin 81 mg, ticagrelor 90 mg BID, atorvastatin 80 mg, lisinopril 10 mg, metoprolol succinate 50 mg, with cardiac rehab referral in 3 weeks and follow-up at 4 weeks.
Takeaway: GRACE score in the ED note defines the cath window. Hold P2Y12 until anatomy is known. Use fentanyl over morphine in any acute coronary syndrome patient who has been or will be loaded on a P2Y12 inhibitor.
Protocol Adjustments Experienced Practice Uses Beyond the Standard Guideline
- hs-cTn 0/1h or 0/2h algorithm at first contact — commits ~75% of patients to rule-in or rule-out within 2 hours. Old 4–6-hour serial protocol is obsolete with current assays.
- GRACE score in the ED note drives invasive timing — very high risk <2 h, high risk <24 h, intermediate <72 h, low risk selective. Document the score, not "needs cath."
- Skip P2Y12 pre-treatment; load on the cath table — ESC 2020 + DUBIUS + ISAR-REACT 5. Aspirin 162–325 mg at first contact; hold ticagrelor/prasugrel until coronary anatomy known. Exception: confirmed STEMI activation.
- Fentanyl, not morphine, in any P2Y12-loaded patient — morphine delays oral P2Y12 onset for hours. Fentanyl 25–50 mcg IV titrated; nitroglycerin first; morphine only if refractory.
S6. Pearls, Pitfalls, and FAQ
Pearl 1 — Use Δ troponin, not absolute value
In CKD, sepsis, HF, PE, and chronic myocardial injury, baseline hs-cTn is elevated and stable. The dynamic rise-and-fall pattern over serial measurements (Δ ≥20-50% of URL) is what separates acute MI from chronic injury. A flat 80 ng/L hs-cTn in a dialysis patient with atypical chest pain rarely reflects acute infarction; the same value with a 30% rise at 1h and continuing rise at 3h almost always does.
Pitfall 1 — Treating Type 2 MI with DAPT and cath
Sepsis, hypoxemia, severe HTN, tachyarrhythmia, anemia, and shock all cause troponin elevation through supply-demand mismatch. Aggressive antiplatelet/anticoagulation in this setting harms more than helps — bleeding rises without modifying the underlying mechanism. Treat the precipitant (transfuse, control HR, oxygenate, treat sepsis) and reserve cath for recurrent ischemia after the trigger resolves.
Pearl 2 — aVR ST-elevation = left main equivalent
ST-elevation in aVR ≥1 mm with diffuse ST-depression in ≥6 leads strongly suggests left main, ostial LAD, or three-vessel disease. This is one of the highest-mortality ECG patterns in cardiology — call interventional cardiology immediately, avoid full P2Y12 loading until anatomy known (likely CABG candidate), and prepare for emergent cath.
Pitfall 2 — Pre-loading P2Y12 before knowing anatomy
ISAR-REACT 5 and ACCOAST showed upstream prasugrel/ticagrelor before angiography increased bleeding without ischemic benefit. If CABG is needed, full P2Y12 inhibition mandates 5-7 day delay (ticagrelor: 3-5 days; prasugrel: 7 days; clopidogrel: 5 days), prolonging hospitalization and increasing in-hospital event risk. Wait until anatomy is defined.
Pearl 3 — Dual pathway: rivaroxaban 2.5 mg BID + aspirin
The COMPASS trial established that low-dose rivaroxaban (2.5 mg BID) added to aspirin reduces MACE in stable atherosclerotic disease (post-MI, PAD, stable CAD) at the cost of modest bleeding. In high-ischemic-risk NSTE-ACS patients without high bleed risk, transitioning from DAPT to dual pathway after 12 months may further reduce ischemic events.
Pitfall 3 — Forgetting MINOCA work-up
5-10% of NSTEMIs have non-obstructive coronaries on cath (MINOCA: MI with non-obstructive coronary arteries). This is not "ruled out for ACS" — it requires follow-up with cardiac MRI (myocarditis, takotsubo, infarction patterns), provocation testing (vasospasm), thrombophilia screen if young, and SCAD evaluation in young women. Misclassifying MINOCA as "false positive" misses treatable underlying disease.
Frequently Asked Questions
- Non-ST-Elevation Myocardial Infarction: Risk Stratification and Invasive Strategy
- Long QT Syndrome: Genotype-Specific Diagnosis, Risk Stratification, and Therapy
- Syncope: Evaluation, Risk Stratification, and Management
- Hypertrophic Cardiomyopathy: Diagnosis, Risk Stratification, and Treatment
- Brugada Syndrome: ECG Pattern Recognition, Risk Stratification, and ICD Decision-Making
- Hypertension — Diagnosis, Risk Stratification, and Pharmacotherapy